What's Happening?
Epigenic Therapeutics, a biotechnology company focused on gene modulation therapy, has completed a $60 million Series B financing round. The funding, led by Lapam Capital and supported by existing investors Qiming Venture Partners and OrbiMed, will be used to further the clinical development of EPI-003 for chronic hepatitis B and EPI-001 for hypercholesterolemia. The investment will also accelerate preclinical programs and enhance Epigenic's technology platforms. The company's proprietary EPIREG™ technology platform offers a safer alternative to traditional gene-editing tools by utilizing DNA methylation and histone modification for precise gene silencing.
Why It's Important?
The completion of this financing round is significant for the biotechnology sector, particularly in the field of epigenetic medicine. Epigenic Therapeutics' advancements could lead to safer and more effective treatments for chronic diseases, addressing safety concerns associated with conventional gene editing. The investment underscores the growing interest and potential in epigenetic therapies, which could transform treatment approaches for various diseases. Stakeholders in the healthcare industry, including patients and medical professionals, stand to benefit from these innovative therapies.
What's Next?
Epigenic Therapeutics plans to continue the clinical development of its core pipelines, aiming to deliver safe and effective therapies to patients. The company will leverage the new funding to strengthen its technology platforms and pursue further breakthroughs in clinical development and technological innovation. As Epigenic advances its research, it may attract additional investments and partnerships, potentially expanding its influence in the biotechnology industry.
